Tin tức & Cập nhật

Inhibition of the protein kinase C iota (PKCι) with auranofin and sirolimus does not provide antineoplastic effects in patients with recurrent high-grade serous ovarian cancer, reports a phase II study.

Researchers from the University of Hong Kong found that therapy with the synergistic combination of quizartinib and omacetaxine mepesuccinate (QUIZOM) in acute myeloid leukaemia (AML) patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations produced high rates of composite complete remission (CRc), allowing more AML patients to be bridged to allogeneic haematopoietic stem cell transplantation (HSCT).

Patients who underwent primary cancer site surgery are at greater risk of death from heart disease than the general population, reports a US study.

First-line treatment with immune checkpoint inhibitors (ICIs) is safe and effective in patients with extended stage (ES) small-cell lung cancer (SCLC), but its use as second-line agent is not recommended, according to a study.

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

Individuals who have lost a parent or sibling to cancer at a young age may experience grief-related symptoms for a prolonged period, with a more pronounced effect after sibling loss, according to a review and meta-analysis.

Treatment with sacituzumab tirumotecan (sac-TMT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with previously treated advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) compared with docetaxel, according to the OptiTROP-Lung03 study presented at ELCC 2026.